January 07, 2022
Phapros Expects Double Digit Growth in 2022
PT Phapros Tbk, one of the national pharmaceutical companies in Indonesia, is pretty optimistic that double digit growth will be achieved in 2022. This growth will mainly be driven by the development and innovation of new products.
President Director of Phapros, Hadi Kardoko said that in the midst of current uncertainty, innovation is the key to staying alive. "Throughout 2021, we have launched new nine products which are the result from research and development that are also aligned with the needs of the community,” said the director.
In 2022, the company which is also known as its ticker code, PEHA, also plans to launch up to twelve new products which are expected to boost the company's performance.
"The new products to be launched come from several therapeutic classes, including antibiotics, antidiabetics, anticholesterol, which are first line therapy products, thus adding to the completeness of PT Phapros Tbk's products," Hadi explained. He also added that by 2023, Phapros' new product portfolio will consist of 63% branded and 37% generic.
Previously, at the end of 2021, Phapros launched Cardismo extended release (Cardismo XR) for heart and cardiovascular diseases. Hadi added that Cardismo XR, which is made from the active ingredient Isosorbide mononitrate, is a development of the previous Cardismo Phapros product.
The difference is that Cardismo XR is a slow-release or extended-release (XR) tablet. Initially, patients with coronary heart disease had to take regular Cardismo 2 - 3 times a day, with Cardismo XR, patients only need to take 1 time a day with the effects that can be felt throughout the day, so patient comfort and compliance are guaranteed.